Terms: = Prostate cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Clinical Outcome
26 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.
Cursano MC; Conteduca V; Scarpi E; Gurioli G; Casadei C; Gargiulo S; Altavilla A; Lolli C; Vincenzi B; Tonini G; Santini D; De Giorgi U
Sci Rep; 2022 May; 12(1):7319. PubMed ID: 35513478
[TBL] [Abstract] [Full Text] [Related]
3. Utility of radiomic zones for risk classification and clinical outcome predictions using supervised machine learning during simultaneous
Tu SJ; Tran VT; Teo JM; Chong WC; Tseng JR
Med Phys; 2021 Sep; 48(9):5192-5201. PubMed ID: 34214211
[TBL] [Abstract] [Full Text] [Related]
4. A new bioinformatics approach identifies overexpression of GRB2 as a poor prognostic biomarker for prostate cancer.
Iwata T; Sedukhina AS; Kubota M; Oonuma S; Maeda I; Yoshiike M; Usuba W; Minagawa K; Hames E; Meguro R; Cho S; Chien SHH; Urabe S; Pae S; Palanisamy K; Kumai T; Yudo K; Kikuchi E; Sato K
Sci Rep; 2021 Mar; 11(1):5696. PubMed ID: 33707553
[TBL] [Abstract] [Full Text] [Related]
5. [LAPAROSCOPIC RADICAL prostateCTOMY OF 926 PATIENTS AT THE HIROSHIMA ENDOUROLOGICAL ASSOCIATION].
Mita K; Kobatake K; Kohada Y; Naito M; Fukuoka K; Kitano H; Hisatome Y; Seno Y; Goto K; Goriki A; Shinmei S; Nagamatsu H; Iwamoto H; Fukada S; Satake H; Shimamoto T; Fukuhara H; Tamura K; Ohara S; Koda S; Mochizuki H; Kato M; Kadonishi Y; Mutaguchi K; Shigeta M
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):1-11. PubMed ID: 31956211
[TBL] [Abstract] [Full Text] [Related]
6. The Terry Fox Research Institute Canadian prostate cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.
Ouellet V; Aprikian A; Bergeron A; Brimo F; Bristow RG; Chevalier S; Drachenberg D; Fazli L; Fleshner NE; Gleave M; Karakiewicz P; Klotz L; Lacombe L; Lattouf JB; van der Kwast T; Squire JA; Latour M; Trudel D; Mes-Masson AM; Saad F
BMC Urol; 2018 Sep; 18(1):78. PubMed ID: 30200929
[TBL] [Abstract] [Full Text] [Related]
7. Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7.
Verhoef EI; Kweldam CF; Kümmerlin IP; Nieboer D; Bangma CH; Incrocci L; van der Kwast TH; Roobol MJ; van Leenders GJ
Histopathology; 2018 Apr; 72(5):760-765. PubMed ID: 29094386
[TBL] [Abstract] [Full Text] [Related]
8. Genomic Gain of 16p13.3 in prostate cancer Predicts Poor clinical outcome after Surgical Intervention.
Bramhecha YM; Guérard KP; Rouzbeh S; Scarlata E; Brimo F; Chevalier S; Hamel L; Dragomir A; Aprikian AG; Lapointe J
Mol Cancer Res; 2018 Jan; 16(1):115-123. PubMed ID: 28993510
[TBL] [Abstract] [Full Text] [Related]
9. Predictive efficacy of the 2014 International Society of Urological Pathology Gleason grading system in initially diagnosed metastatic prostate cancer.
Sun GX; Shen PF; Zhang XM; Gong J; Gui HJ; Shu KP; Liu JD; Zhao J; Yang YJ; Chen XQ; Chen N; Zeng H
Asian J Androl; 2017; 19(5):573-578. PubMed ID: 27569001
[TBL] [Abstract] [Full Text] [Related]
10. The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort.
Saeter T; Bogaard M; Vlatkovic L; Waaler G; Servoll E; Nesland JM; Axcrona K; Axcrona U
Prostate; 2016 Feb; 76(2):207-14. PubMed ID: 26477789
[TBL] [Abstract] [Full Text] [Related]
11. DNA Methylation-Guided Prediction of clinical Failure in High-Risk prostate cancer.
Litovkin K; Van Eynde A; Joniau S; Lerut E; Laenen A; Gevaert T; Gevaert O; Spahn M; Kneitz B; Gramme P; Helleputte T; Isebaert S; Haustermans K; Bollen M
PLoS One; 2015; 10(6):e0130651. PubMed ID: 26086362
[TBL] [Abstract] [Full Text] [Related]
12. The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy.
Servoll E; Vlatkovic L; Sæter T; Nesland JM; Axcrona U; Waaler G; Axcrona K
Urol Int; 2014; 93(3):289-95. PubMed ID: 25170745
[TBL] [Abstract] [Full Text] [Related]
13. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
[TBL] [Abstract] [Full Text] [Related]
14. The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer.
Forootan FS; Forootan SS; Malki MI; Chen D; Li G; Lin K; Rudland PS; Foster CS; Ke Y
Int J Oncol; 2014 Jan; 44(1):265-75. PubMed ID: 24189640
[TBL] [Abstract] [Full Text] [Related]
15. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract] [Full Text] [Related]
16. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.
Jackson W; Hamstra DA; Johnson S; Zhou J; Foster B; Foster C; Li D; Song Y; Palapattu GS; Kunju LP; Mehra R; Feng FY
Cancer; 2013 Sep; 119(18):3287-94. PubMed ID: 23821578
[TBL] [Abstract] [Full Text] [Related]
17. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.
Feng FY; Qian Y; Stenmark MH; Halverson S; Blas K; Vance S; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e361-7. PubMed ID: 21820250
[TBL] [Abstract] [Full Text] [Related]
18. The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.
Barqawi AB; Turcanu R; Gamito EJ; Lucia SM; O'Donnell CI; Crawford ED; La Rosa DD; La Rosa FG
Int J Clin Exp Pathol; 2011 Jun; 4(5):468-75. PubMed ID: 21738818
[TBL] [Abstract] [Full Text] [Related]
19. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients.
Zhang Y; Forootan SS; Liu D; Barraclough R; Foster CS; Rudland PS; Ke Y
Prostate Cancer Prostatic Dis; 2007; 10(3):293-300. PubMed ID: 17457305
[TBL] [Abstract] [Full Text] [Related]
20. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
D'Ambrosio DJ; Hanlon AL; Al-Saleem T; Feigenberg SJ; Horwitz EM; Uzzo RG; Pollack A; Buyyounouski MK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1082-7. PubMed ID: 17241749
[TBL] [Abstract] [Full Text] [Related]
[Next]
